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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
dapsone gel is safe and effective for the treatment of acne vulgaris. 
STUDY DESIGN: A review of three English language studies published in 2007. Includes two 
randomized, double-blind, controlled trials and one open label, noncomparative study. 
DATA SOURCES: Randomized, controlled trials comparing dapsone gel to vehicle gel control 
were found using PubMed and Cochrane database.  
OUTCOMES MEASURED: Success on the Global Acne Assessment Score (GAAS) and 
reduction in acne lesion counts 
RESULTS: The two randomized, controlled trials and the open-label noncomparative study 
showed that dapsone gel was effective in the treatment of acne vulgaris. Results from the Draelos 
et al and Raimer et al studies showed patients had success on the GAAS and had a reduction in 
acne lesion counts. The Lucky et al study showed that patients had a reduction in acne lesions 
counts. All three studies also demonstrated that dapsone gel was safe when used to treat acne 
vulgaris.  
CONCLUSIONS: The results of the randomized, controlled trials and open-label 
noncomparative study indicate that dapsone gel for the treatment of acne vulgaris is safe and 
effective.   
KEY WORDS: Dapsone, acne.  
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INTRODUCTION 
Acne vulgaris is a common dermatologic condition that presents in adolescence and is 
characterized by inflammatory lesions (papules and pustules) and non-inflammatory lesions 
(comedones).1 Acne vulgaris can be chronic for some individuals but self-limiting in other cases. 
Acne vulgaris tends to be more severe in males than females. Contributing factors to developing 
acne include stress, genetics, and environment. Acne vulgaris may negatively impact body 
image, self-esteem, and mood.2 Successful and prompt treatment of acne vulgaris can improve an 
individual’s quality of life.2 
In the United States, acne is the most common skin disorder affecting 40 to 50 million 
individuals.3 The prevalence of acne vulgaris peaks during the middle to late teenage period and 
then steadily decreases. The incidence of acne vulgaris is 30% to 60% of 10-12 year olds and 
80% to 95% of 16-18-year olds that are affected.4 The direct costs associated with acne vulgaris 
surpass $2.2 billion each year in the United States.5 Due to the numerous individuals affected by 
acne vulgaris, this condition is commonly encountered in the scope of PA practice. It is 
important to be able to correctly diagnose and treat acne vulgaris. 
The pathogenesis of acne vulgaris includes many factors and the series of events in the 
process of development of acne are unclear.6 Acne development is initiated during menarche 
when there is increasing sebum production in the sebaceous glands.6 During menarche, the 
adrenal glands, ovaries, and testes secrete androgens. This subsequently leads to an increase in 
sebum production, causing hair follicles to be plugged with oil and dead skin cells that further 
stimulate the development of acne.6 Other known factors that contribute to acne vulgaris are 
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inflammation, follicular hyperproliferation, and Propionibacterium acnes.6 Common locations for 
acne to develop include the face, neck, chest, shoulders, and back.  
Acne vulgaris can be treated with a variety of medications or, simply, self-care. 
Treatment of acne will help to fight bacterial infections, accelerate skin turnover, reduce 
inflammation, and/or reduce oil production. Treatment options vary with each patient, depending 
on the severity of acne. Some options include accutane, tretinoin, azelaic acid, benzoyl peroxide, 
sulfer, salicyclic acid, resorcinol, or routine face washing with mild soap.4 Antibiotics that can be 
used for acne include tetracycline, doxycycline, erythromycin, trimethoprim, and clindamycin.4 
Prompt treatment is crucial because acne vulgaris can cause psychological or social dysfunction 
and long-lasting deformity.  
 The treatment options that are listed above are all successful ways of treating acne. 
Dapsone is a sulfone that has anti-inflammatory and antimicrobial properties.  Dapsone has been 
used orally for the treatment of acne, but is limited in use due to the potential for systemic 
absorption leading to toxicity. Recently, topical dapsone gel was developed for treatment of 
acne, which would offer the same antimicrobial and anti-inflammatory advantage with minimal 
systemic absorption. Thus, dapsone gel offers a new treatment option for acne vulgaris.   
 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “Is dapsone 
gel safe and effective for the treatment of acne vulgaris?” 
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METHODS 
 This review includes two randomized controlled trials and one open-label non-
comparative study. The intervention used was dapsone gel 5%. The treatment groups receiving 
dapsone gel were compared to those receiving vehicle gel control treatment. The population in 
these studies consisted of men and women over the age of 12 years with acne vulgaris. The 
outcomes measured were those of patient-oriented evidence. The efficacy and safety of dapsone 
gel for the treatment of acne vulgaris was measured through success on the GAAS (global acne 
assessment score) and reduction in acne lesion count. Safety of dapsone gel was specifically 
evaluated through adverse events and physical examination findings.  
 The three studies in this review were researched using PubMed and Cochrane database 
by the author. Keywords used in literature search were “dapsone” and “acne”. All articles were 
published in English in peer-reviewed journals in 2007. Articles were selected by the author 
based on their relevance and outcome to the patient. Inclusion criteria were randomized, 
controlled, double-blind studies based on an outcome which was important to the patient. Studies 
were excluded if they included patients under the age of 12 years old. Table 1 demonstrates the 
demographics of the studies included. Statistics included in the studies were relative risk 
reduction (RRR), absolute risk reduction (ARR), relative risk increase (RRI), absolute risk 
increase (ARI), number needed to treat (NNT), number needed to harm (NNH), and p-values. 
 Both Draelos et al and Raimer et al studies were designed in a similar way. Patients were 
randomly assigned dapsone gel or vehicle gel and then instructed to apply a thin layer of dapsone 
or vehicle gel to the acne-affected areas for 12 weeks. In Lucky et al study, patients applied 
dapsone gel to acne-involved areas for 12 months. In this study, if acne cleared up in a particular 
area, treatment could be discontinued but if acne recurred, then dapsone gel was reapplied.  
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OUTCOMES MEASURED 
Outcomes measured were those of patient-oriented evidence that matters. Draelos et al 
and Raimer et al studies assessed efficacy based on success rates on the GAAS from 0 to 4 
(0=none, 1=minimal, 2=mild, 3=moderate,4=severe) and reduction from baseline in acne lesion 
counts. Success on the GAAS is defined as a score of 0 or 1. Patients went through a 
dermatologic examination at baseline and weeks 2, 4, 6, 8, and 12. At these visits, a Global Acne 
Assessment Score was recorded. In addition, at baseline and week 12, inflammatory, non-
inflammatory and total lesions were counted. The Lucky et al study assessed efficacy based on 
reduction of acne count lesions during a dermatological examination at baseline and months 1, 3, 
6, 9, and 12. 
Another outcome measured was safety of dapsone gel. This was evaluated by the adverse 
events and physical examination findings. All three studies assessed patients for dryness, 
peeling, and erythema. Additionally, blood was drawn for routine laboratory tests and patients 
were screened for G6PD deficiency.  
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Table 1: Demographics & Characteristics of included studies  
Study Type # Pts Age Inclusion Criteria Exclusion 
Criteria 
W/D Intervention 
Draelos6 
(2007) 
Double 
blind, 
RCT 
3010 > 12 
years old 
- Atleast 12 years 
old with a clinical 
diagnosis of acne 
vulgaris 
involving face  
- 20-50 
inflammatory 
lesions and 20-
100 
noninflammatory 
lesions above the 
mandibular 
baseline 
 
 
- Severe cystic 
acne or active/ 
developing 
nodules  
- Use of drugs 
that affect acne 
- Allergy to 
dapsone or 
sulfa drugs  
- Pregnant or 
nursing women 
503 dapsone gel 
5% twice 
daily or  
vehicle gel 
control 
Raimer2 
(2007) 
Double 
blind, 
RCT 
1306 >12 years 
old 
(sub-
group 
presented 
in this 
study is 
12-15 
years old) 
- 12 years or 
older with acne 
vulgaris;  
- presence of 20-
50 inflammatory 
lesions and 20-
100 
noninflammatory 
lesions above the 
mandibular line 
at baseline 
N/A 22 dapsone gel 
5% twice 
daily or 
vehicle gel 
control 
Lucky1 
(2007) 
Open 
label, 
noncom-
parative 
506 >12 years 
old 
- 12 years or 
older with a 
clinical diagnosis 
of moderate to 
moderately 
severe acne 
vulgaris defined 
as at least 20 
inflammatory 
lesions at 
baseline  
- Severe cystic 
acne, acne 
conglobate, or 
active/developi
ng nodules  
- Use of drugs 
that affect acne 
- Allergy to 
dapsone or 
sulfa drugs  
- Pregnant or 
nursing women 
166 dapsone gel 
5% twice 
daily 
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RESULTS 
 This EBM review was done on two randomized controlled trials and one open-label non-
comparative study. The results in these reviews were presented as dichotomous data. Data from 
the studies was analyzed with the intention to treat. The inclusion criteria for all three studies 
was similar. All participants were at least 12 years old with a clinical diagnosis of acne vulgaris 
and had the presence of at least 20 inflammatory lesions at baseline. The Draelos et al and Lucky 
et al studies had similar exclusion criteria whereas the Raimer et al study did not have an 
exclusion criteria noted. Exclusion criteria included severe cystic acne, active/developing 
nodules, pregnant or nursing women, allergy to dapsone or sulfa drugs, or the use of other drugs 
that affect acne.  
 In the study done by Draelos et al, patients treated with dapsone gel had significantly 
greater reduction in inflammatory, non-inflammatory, and total lesion counts from baseline to 12 
weeks and achieved success on the GAAS. The relative risk reduction (RRR) was 23% and 
absolute risk reduction (AAR) was 8.3%. The number needed to treat (NNT) was 13 patients. 
This implies that 13 people needed to be treated with dapsone gel in order to improve acne 
vulgaris in one patient. The difference in control and experimental group was a p-value less than 
0.001, making it statistically significant.  
 In the study done by Raimer et al, dapsone gel was more effective than vehicle gel. At 
week 12 patients achieved GAAS success and reduction in acne lesion counts from baseline. The 
relative risk reduction (RRR) was 42% and absolute risk reduction was 11.9%. The number 
needed to treat was 9 patients. Thus, 9 patients needed to be treated with dapsone gel to improve 
acne vulgaris in one patient. Testing was statistically significant with a p-value less than 0.001. 
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 In the open-label non-comparative study done by Lucky et al, there was a reduction in 
acne count lesions from baseline to 12 months with the use of dapsone gel. Inflammatory lesions 
decreased the greatest by 58.2% and non-inflammatory lesions decreased by 19.5%. Total acne 
lesion counts decreased by 49.0%. The test was statistically significant with a p-value of less 
than 0.001. Table 2 shows the efficacy of dapsone gel in the treatment of acne vulgaris in two of 
the three studies. The study done by Lucky et al is not included in Table 2 because it did not use 
the GAAS score to evaluate effectiveness. 
 
Table 2. Clinical efficacy of dapsone gel in the treatment of acne vulgaris  
Study EER 
(Dapsone 
gel; 
Individuals 
achieving 
success on 
GAAS) 
CER 
(Vehicle 
gel 
control; 
Individuals 
achieving 
success on 
GAAS) 
p-value RRR ARR NNT 
Draelos  
et al 
(2007) 
44.2% 35.9% p<0.001 23% 8.3% 13 
Raimer  
et al 
(2007) 
 
40.1% 28.2% p<0.001 42% 11.9% 9 
Lucky 
et al 
(2007) 
- - - - - - 
EER – experimental event rate, CER – control event rate, RRR – relative risk reduction,       
ARR – absolute risk reduction, NNT – number needed to treat 
 
 
 The incidence of adverse events was also calculated by each study in regards to the safety 
of dapsone gel. In the study done by Draelos et al, both dapsone gel and vehicle gel treated 
groups experienced similar rates of adverse events. Patients treated with dapsone gel had an 
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incidence of 58.2% and patients treated with vehicle gel had an incidence of 58.6% in terms of 
adverse events. Erythema occurred in 16.3% of dapsone treated patients and 16.1% of vehicle 
gel treated patients. The relative risk increase (RRI) was 1.2% and the absolute risk increase 
(ARI) was 0.2%. The number needed to harm (NNH) was 500 patients. Thus, 500 patients need 
to be treated with dapsone gel for one person to have erythema as an adverse event.  
 In the study done by Raimer et al, erythema was one of the most common adverse events 
occurring at week 12. The relative risk increase (RRI) was -11.4% and absolute risk increase 
(ARI) was -4.3%. The number needed to harm (NNH) was 23 patients. 
 The study conducted by Lucky et al found 68% of patients experienced at least one 
adverse event. About 1.6% of patients experienced erythema at application site. Erythema was a 
common adverse event in all three studies. Table 3 shows the incidence of erythema in patients 
treated with dapsone gel versus vehicle gel treated groups.  
 
Table 3. Incidence of erythema in dapsone gel group versus vehicle gel control group. 
 
Study EER 
(dapsone gel)  
CER 
(vehicle gel 
control) 
RRI ARI NNH 
Draelos  
et al 
(2007) 
16.3% 16.1% 1.2% 0.02% 500 
Raimer 
et al 
(2007) 
33.4% 37.7% -11.4%  -4.3%   -23 
 
Lucky 
et al 
(2007) 
1.6% N/A N/A N/A N/A 
EER – experimental event rate, CER – control event rate, RRI – relative risk increase,            
ARI – absolute risk increase, NNH – number needed to harm, N/A – not applicable  
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DISCUSSION 
 Dapsone was shown to be effective for the treatment of acne vulgaris years ago, but was 
not widespread in use due to its systemic toxicity. Dapsone has antimicrobial and anti-
inflammatory properties. Dapsone was known to cause adverse hemolytic reactions, more 
commonly in patients with G6PD deficiency.6 
 The two randomized controlled trials and one open-label noncomparative study showed 
that dapsone gel 5% is safe and effective for the treatment of acne vulgaris. Topical dapsone gel 
has minimal systemic absorption, as noted by the studies discussed. Adverse events and routine 
blood laboratory values were monitored on patients during the study, which showed similar 
results between the dapsone gel treated group and vehicle gel treated group. A major concern 
was patients diagnosed with G6PD deficiency, but no mean change from baseline was seen in the 
hematology results.  
 The study done by Draelos et al showed a higher percentage of people having minimal to 
no acne at the end of the treatment in patients treated with dapsone gel. In addition, those treated 
with dapsone gel had greater success on the GAAS and a reduction in acne lesion counts. 
Erythema was a common adverse reaction seen in both groups that were treated but declined 
with the course of treatment. In the study conducted by Raimer et al, dapsone gel also caused 
improvement of acne based on GAAS success and reduction in acne count lesions. Greatest 
improvement was seen in inflammatory lesions. In the study done by Lucky et al, it is difficult to 
assess efficacy without a control group. However, this study did assess the use of dapsone gel for 
twelve months rather than only twelve weeks.  
 The studies in this review have some limitations. The studies done by Draelos et al and 
Raimer et al were twelve weeks long, which may not be enough time to thoroughly assess 
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efficacy of dapsone gel. For many patients, acne can be a chronically debilitating condition 
where a longer treatment period may be needed. Also, the study done by Raimer et al only 
focused on a subgroup of participants from 12 to 15 years of age. Even though acne vulgaris is 
more common in young teenagers and adolescents, many older individuals are also affected and 
should have been represented. In addition, the study done by Lucky et al lacked a control group. 
Lack of a control group can limit findings and be inconclusive about the efficacy and safety of 
dapsone.  
 
CONCLUSION 
 The trials reviewed imply that dapsone gel is safe and effective for the treatment of acne 
vulgaris. Patients in all three studies showed improvement in acne vulgaris when applying 
topical dapsone gel. It was also suggested from these studies that dapsone gel is well-tolerated, 
as it does not cause significant adverse events. Additionally, dapsone gel has a rapid onset of 
action, which truly matters to the patient. Dapsone gel provides a new treatment option for 
medial providers and those diagnosed with acne vulgaris. Although these studies do conclude the 
use of dapsone gel is safe and effective, more trials should be done to assess the safety of using 
dapsone gel over a chronic time period. Regardless of the need for additional studies, dapsone 
gel is a safe and effective way of treating acne vulgaris.  
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